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Abstract
Histone H3 lysine 4 (K4) methylation is a prevalent mark associated with transcription activation and is mainly catalyzed by
the MLL/SET1 family histone methyltransferases. A common feature of the mammalian MLL/SET1 complexes is the presence
of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain. Unlike most other
histone lysine methyltransferases, all four proteins are required for efficient H3 K4 methylation. Despite extensive efforts,
mechanisms for how three core components regulate MLL/SET1 methyltransferase activity remain elusive. Here we show
that a heterodimer of Ash2L and RbBP5 has intrinsic histone methyltransferase activity. This activity requires the highly
conserved SPRY domain of Ash2L and a short peptide of RbBP5. We demonstrate that both Ash2L and the MLL1 SET domain
are capable of binding to S-adenosyl-L- [methyl-
3H] methionine in the MLL1 core complex. Mutations in the MLL1 SET
domain that fail to support overall H3 K4 methylation also compromise SAM binding by Ash2L. Taken together, our results
show that the Ash2L/RbBP5 heterodimer plays a critical role in the overall catalysis of MLL1 mediated H3 K4 methylation.
The results we describe here provide mechanistic insights for unique regulation of the MLL1 methyltransferase activity. It
suggests that both Ash2L/RbBP5 and the MLL1 SET domain make direct contacts with the substrates and contribute to the
formation of a joint catalytic center. Given the shared core configuration among all MLL/SET1 family HMTs, it will be
interesting to test whether the mechanism we describe here can be generalized to other MLL/SET1 family members in the
future.
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Introduction
MLL1 (mixed lineage leukemia) is a mammalian homolog of the
Drosophila Trithorax protein (Trx). It is essential for definitive
hematopoiesis by regulating transcription activation of Hox genes
(e.g. Hoxa9 and Meis1), which encode transcription/regulatory
factors promoting hematopoetic stem cell expansion. MLL1 is an
H3 K4 histone methyltransferase (HMT) that effect mono-, di-,
and tri-methylation through its evolutionarily conserved SET (Su
(var), Enhancer of Zeste and Trithorax) domain [1,2,3]. Both
MLL1 and H3 K4 methylation are localized broadly across
promoter, 59 transcribed and coding regions of the critical target
genes and facilitate the recruitment of RNA Pol-II and other
chromatin remodeling activities involved in transcription activa-
tion [4,5,6]. Deregulation of MLL1 is associated with acute
lymphoid and myeloid leukemia [7,8,9]. In most cases, balanced
chromosome translocations occur on one MLL1 allele and result
in leukemogenic MLL1 fusion proteins (e.g. MLL1-AF9, MLL1-
ENL) [7,8]. MLL1 fusion proteins, which lack the C-terminal SET
domain, cooperate with the remaining copy of wild type MLL1 in
leukemogenesis [10,11]. Therefore, understanding the regulation
of MLL1 methyltransferase activity bears clinical significance in
the treatment of MLL1 deregulated leukemia.
MLL1 is one of the MLL/SET1 family HMTs for H3 K4
methylation in higher eukaryotes. MLL/SET1 family HMTs
include SET1A and SET1B [12], the mammalian orthologues of
ySET1, and four MLLs (MLL1-4), which share limited homology
with ySET1 beyond the SET domain [1,3,13,14,15]. Biochemical
studies have shown that MLL/SET1 family histone methyltrans-
ferases share a core configuration that includes three common
proteins: RbBP5, Ash2L and WDR5 [1,3,13,14,15]. The presence
of such a structural core in MLL/SET1 family HMTs implies
common regulatory mechanisms for their enzymatic activities
and/or substrate specificities. Indeed, unlike most histone lysine
methyltransferases, optimal methyltransferase activity for MLL1
depends on its interaction with all three proteins [16]. Using in vitro
biochemical reconstitution, we have demonstrated that a four-
component MLL1 core complex is sufficient to recapitulate most
of the methyltransferase activity of the MLL1 holo-complex,
which is significantly higher than MLL1 alone [16]. Later
biochemical studies have confirmed and further explored the
detailed structural organization of the MLL1 core complex
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important in maintaining the integrity of the MLL1 complex by
directly interacting with MLL1 through a conserved Arginine (R)
residue in the MLL1 pre-SET domain [17,19,20] and with RbBP5
[21]. However, WDR5 by itself does not stimulate methyltrans-
ferase activity of the MLL1 SET domain in vitro [17,20,22]. In
contrast, RbBP5 and Ash2L contribute significantly to the overall
activity of the MLL1 complex despite their lack of stable
association with the MLL1 SET domain in the absence of
WDR5 [16,22]. The mechanism for RbBP5 and Ash2L mediated
stimulation of MLL1 activity remains elusive and is the focus of
this study.
With the exception of Dot1, most histone lysine methyltrans-
ferases contain the evolutionarily conserved SET domain [23].
Biochemical and structural studies revealed that SET domains
usually adopt structures featuring a narrow hydrophobic channel
that links the substrate lysine and S-adenosyl-L- [methyl-
3H]
methionine (SAM) [24]. This lysine access channel, formed by
conserved aromatic residues, is essential for optimal alignment
between the methyl-group of SAM and the e-amine group of the
lysine residue required for efficient catalysis [23,24]. It is also
important for determination of the methylation state specificity
[24]. For most lysine methyltransferases, SET domains alone are
sufficient to carry out the methyl-transfer reaction. Notable
exceptions to the rule are the MLL/SET1 family H3 K4
methyltransferases and the Polycomb group protein EZH2, which
are fully active only in the context of the complexes [16,25,26].
Recent report of the co-crystal structure of the MLL1 SET
domain in complex with AdoHcy and an H3 peptide suggests that
the lysine access channel of MLL1 SET may be widely exposed in
the native protein, rendering it inefficient in aligning the e-amine
of substrate lysine with SAM for optimal catalysis [22]. The
unique structure of the MLL1 SET domain and the requirement
of other proteins for optimal methyltransferase activity support a
hypothesis that other members of the MLL1 complex contribute
to the proper alignment of the substrate lysine with SAM [22].
Recently, a SET domain independent methyltransferase activity
has been reported for the MLL1 core complex [18]. This activity
mainly targets H3 K4 mono-methylation [18]. Here we show that
non-SET proteins RbBP5 and Ash2L, acting as a heterodimer
(referred to as Ash2L/RbBP5 herein), account for this novel
methyltransferase activity. By comprehensive mapping of both
RbBP5 and Ash2L, we found that the Ash2L SPRY domain and a
short RbBP5 peptide are important for both their intrinsic activity
and the overall activity of the MLL1 complex. Importantly,
Ash2L/RbBP5 is able to directly interact with substrates H3 and
SAM and contributes significantly to the overall catalysis of the
MLL1 complex. Our results support a model that Ash2L/RbBP5,
just like the MLL1 SET domain, directly participates in the
catalytic reaction of H3 K4 methylation in the MLL1 complex.
Our study presents a new paradigm for the regulation of histone
lysine methyltransferases.
Results
Ash2L/RbBP5 stimulate MLL1 activity in the absence of
WDR5
In order to study the function of RbBP5 and Ash2L in the
MLL1 complex, we expressed WDR5 (W, D23aa), RbBP5 (R),
Ash2L (A, isoform b, 534aa) and the MLL1 SET domain
(MLL1
SET or M, residues 3754-3969) in E. coli and purified them
to homogeneity respectively (Fig. S1A). The purity of the
recombinant proteins was further confirmed by mass spectrometry
(data not shown). Different combinations of these four proteins
were mixed together and tested for HMT activity in vitro.
Consistent with previous studies [16,22], dramatic increase in
H3 methylation was observed when stoichiometric quantities of
four core components were present (Fig. 1A, lane 6 vs 2).
Surprisingly, RbBP5 and Ash2L were able to stimulate the
MLL1
SET activity to the same level as the four-component
complex (MWAR) at 5 mM concentration for each protein
(Fig. 1A, lane 5 vs 6). In contrast, WDR5, which makes direct
contact with MLL1 through a ‘‘WIN’’ motif [19,20], could not
stimulate MLL1 activity at the same assay condition in vitro
(Fig. 1A, lane 3 vs lane 2). Given the essential role of WDR5 in
maintaining the integrity of the MLL1 complex and in H3 K4
methylation in vivo [16,27], we further compared the methyltrans-
ferase activity of the four-component complex with that of the
three-component mixture (MAR) at different complex concentra-
tions. As shown in Fig. 1B, we found that the requirement of
WDR5 in overall methyltransferase activity was sensitive to
complex concentration (Fig. 1B). When complex concentration
was low (e.g. 0.5 mM), there was ,10-fold difference in activities of
MWAR versus MAR (Fig. 1B). In contrast, when complex
concentration was high (e.g. 5 mM), the difference was reduced to
,2 fold. Given that neither RbBP5 nor Ash2L stably interacts
with MLL1
SET in the absence of WDR5 [16,22] and that their
stimulatory effects to MLL1
SET activity are more apparent at high
complex concentration, it is likely that some previously unchar-
acterized transient interactions between Ash2L/RbBP5 and
MLL1
SET are important for catalyzing H3 K4 methylation.
RbBP5 and Ash2L function as a heterodimer
In order to study the underlying mechanism for Ash2L/RbBP5
mediated stimulation of MLL1
SET activity, we first mapped Ash2L
and RbBP5 for minimal domains that support the overall activity
of the MLL1 core complex. As shown in Fig. 1, Ash2L C-terminal
SPRY domain (Fig. 1C) and a short RbBP5 peptide (330-356aa)
(Fig. 1D) were sufficient to stimulate the activity of MLL1
SET. For
all reactions in Fig. 1C and 1D, equal molar amount of proteins or
peptides were used. RbBP5 peptides were run out of the gel due to
their small sizes (Fig. 1D). The Ash2L SPRY domain is
evolutionarily conserved, with ,50% sequence identity/similarity
among Ash2L homologues in Homo sapiens, Drosophila, S. cerevisiae
and Tetrahymena thermophila (Fig. S2). It has been proposed that the
SPRY domain is a protein-protein interaction domain [28,29].
Unlike Ash2L, the required RbBP5 peptide (330-356aa) is highly
acidic, with 30% residues being glutamic acid (E) or aspartic acid
(D). By the thermal shift assay [30], this RbBP5 peptide (330-
356aa) did not show any thermal transition, suggesting no
secondary structure in solution (Fig. S3). Interestingly, it includes
residues 350–356 that are essential for Ash2L interaction [16].
Deleting this Ash2L interacting region in RbBP5 abolished the
Ash2L/RbBP5 dependent stimulation of the MLL1
SET activity
(Fig. 1D, lane 4). This result suggests that Ash2L and RbBP5
probably function together as a heterodimer in the complex. This
is consistent with the observation that neither RbBP5 nor Ash2L
alone was able to stimulate MLL1
SET activity to the same extent as
when they were together (Fig. 1A and data not shown).
Ash2L/RbBP5 has intrinsic methyltransferase activity
Given the reported presence of a SET domain independent
methyltransferase activity in the MLL1 core complex [18], we
tested whether RbBP5 and Ash2L possess intrinsic histone
methyltransferase activity. Using in vitro HMT assays, we found
that Ash2L/RbBP5 exhibited intrinsic HMT activity for histone
H3 (Fig. 2A). As shown in Fig. 2A, Ash2L/RbBP5 demonstrated
specificity mainly towards H3 K4 (Fig. 2A). Mutation of K4, but
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RbBP5. When H3 peptides carrying one, two or three methyl-
groups at K4 were used as the substrates, Ash2L/RbBP5 was
more efficient in methylating unmodified H3 peptides (Fig. 2B). In
contrast to both MLL1
SET and the MLL1 core complex, activity
of Ash2L/RbBP5 on H3 peptides with mono- or di-methylated
K4 was minimal (Fig. 2B). H3 peptide with tri-methylated K4 was
used as the negative control (Fig. 2B). This result was reminiscent
of what was described previously for the SET-independent activity
of the WAR complex [18]. Of note, the activity we observed for
Ash2L/RbBP5 was much weaker compared to MLL1
SET and
required long exposure for detection (Fig. 2B). Further character-
ization showed that the same domains in Ash2L and RbBP5 that
were important for overall H3 methylation also supported the
intrinsic methyltransferase activity. As shown in Fig. 2C, the
Ash2L SPRY domain and RbBP5 330-356aa were capable of
methylating recombinant histone H3 in the in vitro HMT assays
even though they were less active compared to full-length proteins.
Figure 1. Ash2L/RbBP5 stimulates MLL1 activity in the absence of WDR5. (A) In vitro HMT assay for MLL1
SET and MLL1
SET with one, two or
three components of the MLL1 complex as indicated on top. For all reactions, 5 mM of MLL1
SET was used and all other MLL1 core components were
added at equal molar concentration. (B) Scintillation count for in vitro HMT assays using either four-component complex MWAR or three-component
mixture MAR as enzymes. Y-axis, scintillation counts (cpm) for the methylation reaction. X-axis, molar concentration of MLL1
SET used in different
reactions. Other proteins were added at equal molar concentration to MLL1
SET in each reaction. All experiments were repeated for three times. The
error bar represented standard deviation. (C) In vitro HMT assay using various Ash2L fragments as indicated on top. Top panel, fluorogram of
methylated H3. Bottom two panels, Coomassie stained gels for H3 substrate and the MLL1 core components used in the same reaction. (D) In vitro
HMT assay using various RbBP5 peptides at equal molar concentration (5 mM) as indicated on top. Top panel, fluorogram of methylated H3. Bottom
two panels, Coomassie stained gels for H3 substrate and the MLL1 core components used in the same reaction. Ash2L
SPRY and MLL1
SET were run at
about the same position. RbBP5 peptides were run out of the gel due to their small sizes.
doi:10.1371/journal.pone.0014102.g001
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peptides suggest that other sequences in Ash2L or RbBP5 may
also be important for the intrinsic activity of the Ash2L/RbBP5
heterodimer. In addition, neither Ash2L nor RbBP5 alone had
any detectable HMT activity under the same assay condition
(Fig. 2B and 2C).
Ash2L is capable of binding to substrate SAM
Given the intrinsicactivity oftheAsh2L/RbBP5 heterodimer, we
next examined whether it bound to substrate SAM, an essential step
in catalysis.We found that Ash2L was capable of bindingto SAMin
the presence of RbBP5 and MLL1
SET after UV treatment (Fig. 3A).
In contrast, no SAM binding by RbBP5 was detected in the same
reaction (Fig. 3A). SAM binding by Ash2L was UV-dependent and
could be competed off by excess amount of unlabeled SAM (1000
fold, ,0.35 mM) (Fig. 3A). As a control, excess amount of ATP
(1000 fold, ,0.35 mM) could not compete off the SAM binding by
Ash2L or MLL1
SET. Interestingly, stable Ash2L SAM binding
required both RbBP5 and MLL1
SET. As shown in Fig. 3B, SAM-
binding by Ash2L was severely comprised when MLL1
SET and
RbBP5 were either sub-stoichiometric or absent. Quantitation of
Ash2L SAM binding in Fig. 3B was included in Fig. 3C. In contrast
to Ash2L, MLL1
SET-SAM interaction was stable and was not
affected by Ash2L/RbBP5 (Fig. 3D). Adding excess amount of
Figure 2. Ash2L/RbBP5 has intrinsic methyltransferase activity. (A) In vitro HMT assay using ,5 mM Ash2L/RbBP5 heterodimer as enzymes.
Top, fluorogram of methylated H3 after three weeks of exposure. Bottom, Coomassie stained gels for H3 substrate. (B) In vitro HMT assay using 60 mM
unmodified, mono-, di- and tri-methylated H3 K4 peptides as substrates. The proteins (,5 mM final concentration) in each reaction were indicated on
bottom. In vitro HAT assay using p300 was included as a quality and loading control for H3 peptides. The exposure times for the top and bottom
panels were different and were indicated on bottom. (C) Left, in vitro HMT assay for Ash2L, Ash2L/RbBP5 as well as Ash2L
SPRY/RbBP5
1-410. Right, in
vitro HMT assay for Ash2L
SPRY and various RbBP5 peptides as indicated on top. Coomassie stained gels for H3 and proteins used in the assays were
included on bottom.
doi:10.1371/journal.pone.0014102.g002
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SET did not enhance SAM
binding by wild type MLL1
SET. However, Ash2L/RbBP5 was able
to partially rescue the SAM binding deficiency of the MLL1
SET
mutant H3907A, which was deficient in SAM binding by itself
(Fig. 3D) [3]. Quantitation of Ash2L SAM binding in Fig. 3D was
included in Fig. 3E. These results suggest that two proteins in the
MLL1corecomplex(i.e.Ash2LandMLL1
SET)arecapableofSAM
binding and their interactions with SAM can potentially be
influenced by each other.
Mutations that disrupt RbBP5 and Ash2L interaction
abolish Ash2L SAM binding and H3 K4 methylation
Given the importance of RbBP5 and Ash2L interaction in the
overall H3 K4 methylation, we next tested whether disrupting
RbBP5 and Ash2L interaction by site-directed mutagenesis
reduced SAM binding by Ash2L. As previously demonstrated,
the minimal Ash2L interacting region in RbBP5 (350-356aa) is
highly acidic, with 30% residues being glutamic acid (E) or aspartic
acid (D). We reason that the residues in Ash2L that are important
for RbBP5 interaction may involve positively charged residues
such as Lysine (K) or Arginine (R). By sequence alignment, we
found that a couple of Arginine residues in Ash2L were highly
conserved through evolution (square, Fig. S2). Mutating one of
them, R343A, completely abolished Ash2L interaction with
RbBP5 (Fig. 4A). Reciprocally, we also introduced mutations
F352S/D353G to RbBP5 (RbBP5
SG), which was previously
showed to disrupt Ash2L interaction [16](Fig. 4A). When
RbBP5
SG or Ash2L
R343A mutant was used in the in vitro HMT
Figure 3. Ash2L/RbBP5 binds to substrate SAM. (A) SAM binding assays for Ash2L/RbBP5 and MLL1
SET by UV cross-linking. Left, SAM binding
assays for the MLL1 core complex with or without UV cross-linking. Equal molar (,3 mM) of each MLL1 core component was used. Right, SAM binding
by Ash2L and MLL1
SET could be chased off by 1000x excess cold SAM (,0.35 mM) but not by ATP (,0.35 mM). Black lines indicated expected
positions for each protein. 10-fold molar excess of Ash2L/RbBP5 (relative to MLL1
SET) was used in this experiment to reduce the exposure time for
detecting Ash2L SAM binding. Black lines indicated expected positions for each protein. (B) SAM binding assay for 3 mM equivalent of Ash2L alone or
Ash2L/RbBP5 in the presence of increasing amount of MLL1
SET. Molar ratios of MLL1
SET versus Ash2L/RbBP5 or Ash2L were indicated on top.
(C) Image-J quantitation of the results in (B). Y-axis, arbitrary unit for pixel count. (D) Reciprocal SAM binding assays as performed in (B) except
,3 mM wild type or H3907A MLL1
SET was mixed with increasing amount of Ash2L/RbBP5. The molar ratios of Ash2L/RbBP5 versus MLL1
SET were
indicated on top. (E) Image-J quantitation of the results in (D). Y-axis, arbitrary unit for pixel count. In (B) and (D), Coomassie staining for the same
gels was included on bottom. The positions for Ash2L and RbBP5 were indicated on left. *, non-specific protein.
doi:10.1371/journal.pone.0014102.g003
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Strikingly, both mutants led to reduction in Ash2L SAM binding
as well even though SAM-binding by MLL1
SET was not affected
(Fig. 4C). The SAM binding deficiency of Ash2L mutant was not
due to protein mis-folding since mutated Ash2L and RbBP5
proteins have similar thermal stability as the wild type proteins in
the thermal shift assay (Table S1) [30]. Taken together, these
results argue that SAM binding by Ash2L probably plays a
previously uncharacterized role in the regulation of the overall
activity of the MLL1 complex.
To further confirm the function of Ash2L in mammaliancells, we
tested the ability of Ash2L
R343A in rescuing global reduction of H3
K4 methylation after RNAi knockdown of endogenous Ash2L [16].
The siRNAs we used specifically targeted 39UTR of Ash2L
transcripts from the endogenous locus. As a result, Ash2L knock-
down led to global down regulation of H3 K4 tri-methylation
(Fig. 4D). H3 K4 mono-methylation was also slightly affected by
Ash2L knockdown. Over-expression of Myc-tagged wild-type
Ash2L in cells treated with Ash2L siRNA partially rescued the
global reduction of H3 K4 tri-methylation. In contrast, over-
expression of Ash2L
R343A could not rescue H3 K4 tri-methylation
defects (Fig. 4D). Immunoblots for H3 and myc-Ash2L were
included as loading and expression controls respectively.
SAM binding by Ash2L, not the intrinsic activity of
MLL1
SET, correlates with overall activity of the MLL1 core
complex
To further study the functions of Ash2L SAM binding, we next
tested its function in the context of MLL1
SET mutants. There are
several previously characterized MLL1
SET mutants including
Y3858F, Y3942A and Y3874A/K3878A [22]. Both Y3858 and
Y3942 are at the catalytic center of the MLL1 SET domain and
Y3942 is important for the state specificity of MLL1
SET alone
[18]. In contrast, Y3874 and K3878 are at the SET-I sub-domain
away from the active center [22]. Consistent with previous
observation [22], the intrinsic activity of these MLL1
SET mutants
did not always align with the overall activity of the MLL1
complex. For example, Y3942A did not affect the MLL1
SET
activity per se but was insufficient to support H3 methylation in
the complex (Fig. 5A). Y3874A/K3878A, on the contrary, was
inactive by itself but was active in the presence of Ash2L/RbBP5
(Fig. 5A). To examine the mechanism underlying the discrepancy
of intrinsic versus overall H3 K4 methyltransferase activity, we
decided to perform SAM binding assays for Ash2L in the context
of different MLL1
SET mutants. To our surprise, we found a
striking correlation between Ash2L SAM binding and the overall
activity of the MLL1 core complex. In the MLL1 complex
containing MLL1
SET Y3858F or Y3942A mutant, which had
minimal overall activity, SAM binding by Ash2L was dramatically
reduced (Fig. 5B). In contrast, SAM binding by Ash2L was only
slightly affected in the complex consisting of double mutants
MLL1
SET Y3874A/K3878A (Fig. 5B, bottom panel), which had
almost no effect on overall activity (Fig. 5A, bottom panel).
Duplicate samples were run for Coomassie gels as the loading
controls. In the several cases we tested, SAM binding by Ash2L
seemed to correlate better with the overall activity of the MLL1
complex than the intrinsic activity of MLL1
SET. These results
argue that SAM binding by Ash2L plays an indispensable role in
the regulation of the overall activity of the MLL1 core complex.
H3 and SAM mediate Ash2L and MLL1
SET interaction
Given the highly synergistic function of Ash2L and MLL1
SET in
H3 K4 methylation and the ability for both proteins to interact
Figure 4. Ash2L/RbBP5 is important for the overall activity of
the MLL1 complex. (A) Co-immunoprecipitation of RbBP5 and Ash2L.
Proteins purified through either Flag tag on RbBP5 or RbBP5 mutant
(left) or His tag on Ash2L or Ash2L mutant (right) were run on SDS-PAGE
for Coomassie staining. (B) In vitro HMT assay for MLL1
SET, Ash2L or
Ash2L R343A mutant and RbBP5 or RbBP5 mutant as indicated on top.
Equal amount of proteins and H3 substrate were used in each reaction.
(C) SAM binding assays using proteins indicated on top. Positions of
Ash2L and MLL1
SET were indicated on right. In (B)-(C), SG refers to
RbBP5 F352S/D353G double mutations. Coomassie stained gels were
included on bottom as controls. (D) HeLa cells were treated with siRNAs
targeting endogenous Ash2L transcripts for 48hrs and then transfected
with plasmids expressing Myc-tagged Ash2L or Ash2L mutant R343A.
Total proteins were separated on SDS-PAGE and blotted for different
antibodies indicated on right. Anti-H3 antibody was used as the loading
control.
doi:10.1371/journal.pone.0014102.g004
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MLL1
SET may interact with the same set of H3 and SAM
substrates at the catalytic center of the MLL1 complex. To test
this, we performed pull-down assays for MLL1
SET and Ash2L/
RbBP5 with or without the presence of H3 or SAM. As shown in
Fig. 6, MLL1
SET was not able to stably interact with Ash2L and
RbBP5 in the absence of WDR5, consistent with our previous
observation [16]. However, in the presence of H3 or methylation
product AdoHcy, MLL1
SET could be partially recovered by Flag-
Ash2L immunoprecipitation (Fig. 6A). The pull-down efficiency
Figure 5. Ash2L/RbBP5 and MLL1
SET coordinate in H3 K4 methylation. (A) In vitro HMT assays using ,5 mM of wild type and mutants
MLL1
SET either alone (top) or with Ash2L/RbBP5 (bottom) as enzymes (B) SAM binding assays for Ash2L and either wild type MLL1
SET or SET domain
mutants. 3 mM of wild type MLL1
SET or SET domain mutants was used in each reaction. Molar ratios of Ash2L/RbBP5 versus MLL1
SET were indicated on
top. The positions for Ash2L and RbBP5 were indicated on left. Duplicate samples were run for Coomassie staining as the loading controls.
doi:10.1371/journal.pone.0014102.g005
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SET was further enhanced when both H3 and AdoHcy
were present (Fig. 6A). AdoHcy was used during the IP because
Flag-IP was blocked in the presence of SAM, probably due to
methylation of the M2 antibody by MLL1. Co-purification of
Ash2L/RbBP5 and MLL1
SET in the presence of H3 and AdoHcy
suggests that they probably interact with the same molecules. This
result implies that Ash2L/RbBP5 probably functions at the
catalytic center of the MLL1 core complex or at least in close
proximity to it. The H3- and AdoHcy-dependent stabilization was
only apparent in the absence of WDR5 (data not shown), which
held MLL1 core complex together by simultaneously interacting
with MLL1 and RbBP5 [16,21].
Discussion
Unlike most histone lysine methyltransferases, MLL/SET1
family H3 K4 HMTs are fully active only in the context of a multi-
subunit complex and on a platform comprised of several highly
conserved proteins: WDR5, RbBP5 and Ash2L [16]. Among these
core components, WDR5 stably interacts with the SET domain
through the residue R3765 of MLL1 [17,20]. This interaction is
critical for the integrity of the MLL1 complex [16,17,20]. In
contrast, RbBP5 and Ash2L are not able to stably interact with
MLL1 even though both proteins are capable of stimulating
MLL1 methyltransferase activity [16,22]. Here, we show that
Ash2L/RbBP5 heterodimer has weak intrinsic H3 K4 methyl-
transferase activity (Fig. 2). This activity requires the highly
conserved SPRY domain of Ash2L, as well as its interaction with
RbBP5 (Fig. 2). Importantly, the ability of Ash2L to interact with
H3 and SAM plays an essential role in regulating the overall
activity of the MLL1 complex (Fig. 4 and 5). Our results suggest
that both Ash2L/RbBP5 and MLL1
SET are directly involved in
the catalytic reaction, which is highly unique among histone lysine
methyltransferases. Given the highly conserved core configuration
among MLL/SET1 family HMTs and the global effects of Ash2L
(both wild type and mutants) on H3 K4 methylation in cells, it will
be interesting to test whether the finding in this study is applicable
for the regulation of other MLL/SET1 family members, especially
SET1A/B, the predominant H3 K4 methyltransferases in
mammalian cells [31].
Finding the intrinsic methyltransferase activity for Ash2L/
RbBP5 is surprising since neither protein contains any known
catalytic domain for histone methylation. This activity is
reminiscent of what has recently been reported by Patel et al
[18], even though our activity is much weaker and requires weeks
of exposure for detection. Domain mapping shows that the
minimal domains required for methylation include the highly
conserved SPRY domain at the Ash2L C-terminus and an acidic
polypeptide of 26 amino acids from RbBP5. Given the size of
RbBP5 peptide and Ash2L SAM binding capability (Fig. 3), it is
likely that Ash2L plays a more prominent role in the catalysis
while RbBP5 stabilizes the Ash2L structure. The 250 amino acid
SPRY domain of Ash2L and the closely related B30.2 domain are
found in a diverse group of proteins [32]. Crystal structures of the
SPRY domains in different proteins show that the SPRY domain
usually forms a single-domain b-sandwich fold with one or two a-
helixes and is involved in protein-protein interactions [28,29].
Comparing the known SPRY structures with those of the SET
domains and Dot1, we cannot identify features reminiscent of the
active sites in known histone methyltransferases. Future structure
studies of Ash2L/RbBP5 in complex with SAM and/or H3 are
essential to characterize the molecular mechanism for Ash2L/
RbBP5 mediated catalysis with or without the presence of MLL1.
The exact mechanism for the regulation of MLL/SET1 family
HMTs remains elusive despite extensive effort. Our study here
provides a novel concept that catalysis of H3 K4 methylation by
the MLL1 complex not only involves the well-characterized SET
domain, the catalytic domain for almost all histone lysine
methyltransferases, but also a direct participation of the non-
SET domain protein Ash2L. The crystal structure of MLL1
SET
lends additional support for the requirements of other MLL1
complex components for efficient catalysis [22]. Although H3 and
SAM bind to two different faces of MLL1
SET just as in other SET
domains, the lysine access channel surrounding K4 is relatively
exposed even when MLL1
SET is in complex with H3 peptide and
SAM [22]. This open conformation implies relatively unstable
alignment between H3 and SAM, underlying the poor catalytic
activity. Because of this unique feature, Wilson and colleagues
proposed a model that the interactions among core components
and MLL1
SET might re-order the SET-I sub-domain of MLL1
SET
and convert it to a closed conformation with a tightly formed
lysine access channel [22]. From most well-studied SET domain
structures, the formation of the lysine access channel often involves
insertion of aromatic residues from flexible loop regions of the
post-SET domain such as Y109 in vSET [33], W318 in DIM-5
[34] and Y337 in SET7/9 [35,36]. The aromatic residue inserts
Figure 6. H3 and SAM mediate Ash2L/RbBP5 and MLL1
SET
interaction. (A) 150 nM recombinant proteins Flag-Ash2L, His-RbBP5
and His-MLL1
SET were mixed in the presence of ,7.5 mM histone H3,
,10 mM methylation product AdoHcy or both as indicated on top. After
Flag-IP, eluates from M2 agarose beads were separated on SDS-PAGE
and immunoblotted for MLL1
SET, Ash2L and RbBP5 (indicated on right).
25% input was loaded as the control. (B) ‘‘Single catalytic center’’ model
for the regulation of the MLL1 core complex. In this model, Ash2L/
RbBP5 and MLL1
SET interact with the same H3 substrate and substrate
SAM and form a shared active center for catalysis. This structure is
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However, such an aromatic residue is not easily identifiable in the
SET-I sub-domain of MLL1
SET. In light of our finding that Ash2L
directly interacts with SAM and H3 in the MLL1 complex,
another intriguing scenario is that aromatic residue(s) from
Ash2L/RbBP5 may directly participate in the catalysis and
facilitate the optimal alignment of substrate lysine and SAM
(Figure. 6B). Notably, there are several highly conserved aromatic
residues in Ash2L SPRY (Fig. S2) and RbBP5 that can potentially
fulfill this function. In this model, we envision that Ash2L/RbBP5
and MLL1
SET may come together to form a complete catalytic
center in the MLL1 complex, each providing essential features to
ensure optimal alignment of substrates for catalysis. This structure
can be stabilized by WDR5, which simultaneously interact with
MLL1
SET and RbBP5 [16,18,21]. Several lines of evidence
support this model: 1) Ash2L/RbBP5 rescues SAM binding
deficiency of MLL1
SET Mutant H3907A (Fig. 3D); 2) SAM
binding by Ash2L/RbBP5 correlates with the overall activity of
the MLL1 complex (Fig. 4B, 4C and 5); and 3) Ash2L/RbBP5 and
MLL1
SET co-immunoprecipitate in the presence of H3 and
AdoHcy even when WDR5 is absent (Fig. 6A). Future structural
studies of the MLL1 core complex are imperative to distinguish
these different models.
Inaddition tothe regulationofoverall activity,anotherimportant
aspect of MLL1 regulation, which still remains an open question in
the field, is to understand the regulation of its methylation state
specificity. For most lysine methyltransferase, the specificity for
mono-, di-, or tri-methylation is determined by the presence of a
criticaltyrosineorphenylalanine residueinthelysineaccesschannel
[37]. This residue determines whether the substrate-binding pocket
allows free rotation of substrate lysine for successive addition of up
to three methyl-groups. It has been proposed that Y3942 of
MLL1
SET is a key residue to limit the intrinsic activity of MLL1
SET
to lower methylation [18]. Mutation of Y3942 to phenylalanine
converts MLL1
SET from a mono- to a tri-methyltransferase [18].
However, we found that mutationof Y3942 failed to support overall
activity of the MLL1 complex (Fig. 5A), making it an unlikely
candidate to determine methylation specificity for the MLL1
complex. Therefore, the simple ‘‘F/Y switch’’ model may not be
able to explain the regulation of the state specificity of the MLL1
complex. Novel mechanisms, which await future studies, may be
involved in this process.
Materials and Methods
Plasmid and Expression Vectors
For bacterial expression, SUMO tagged MLL1
SET (Q03164),
Ash2L Full length (NP_001098684.1), Ash2L SPRY and Ash2L
(1-177), WDR5 (D23aa, NP_060058.1), RbBP5 Full length
(NP_005048.2) and RbBP5 peptides fragments were cloned into
pET28a vector (Strategene); Histone H3 and its mutants were
cloned into PET-3d vector. For baculovirus expression, pFastBac
expression vectors (Bacvector 3000, Novagen) were used. Flag-
RbBP5, His-RbBP5 were cloned into EcoRI and HindIII sites of
pFastBac DUAL; His-Ash2L and His- MLL1
SET (3754aa- 3969aa)
were cloned into BamHI and XhoI sites of pFastBac HTb; Flag-
Ash2L was cloned into XhoI and HindIII sites of pFastBac
DUAL. For mammalian expression, Myc-tagged Ash2L was
cloned into pcDNA3 vector. Mutations were introduced by
PCR-based site-directed mutagenesis.
Protein Expression and Purification
E. coli BL21(DE3) cells bearing expression plasmids were
induced for 16 hours with 0.1 mM IPTG at 25uC and cells were
harvested by centrifugation. The cell pellets were resuspended in
lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM NaH2PO4,
400 mM NaCl, 3 mM imidazole, 10% glycerol, 1 mM PMSF,
0.1 mg/ml lysozyme, 2 mM 2-mercaptoethanol, and home-made
protease inhibitor cocktail) and subjected to sonication. The lysate
was cleared by ultracentrifugation at 38,000 rpm for 1 hour and
then incubated with Ni-NTA agarose beads (Qiagen) for 2 hours
at 4uC. The beads were washed by lysis buffer with 10 mM
imidazole for 40 beads volume and the proteins were eluted in
250 mM imidazole. The eluted proteins were digested by ULP1
protease at 4uC overnight to remove SUMO tag. The cleaved
proteins were further purified by gel-filtration chromatography on
Hiload Superdex 200 in buffer A (25 mM Tris-HCl pH 8.0,
150 mM NaCl). For RbBP5 protein, an extra ionic-exchange
chromatography (MonoQ) was used to increase the purity. For
MLL1
SET, protein was cleaved on-column for 3-5 hours using
ULP1 in high salt buffer (50 mM Tri-HCl, 500 mM NaCl, 10%
Glycerol). The purified proteins were concentrated to 10–20 mg/
ml and store at 280uC. For Ash2L/RbBP5 heterodimer, equal
molars of purified Ash2L and RbBP5 proteins were mixed
together, incubated on ice for 30 min and purified through Hiload
Superdex 200 in buffer A.
For baculovirus expressed Flag-Ash2L, His-RbBP5 and His-
MLL1
SET, cell pellets were washed with 1XPBS, resuspended in
lysis buffer (20 mM Tris-HCl pH 7.9, 500 mM KCL, 20%
glycerol, 1 mM PMSF, and 0.05%NP40). The cells were broken
by brief sonication and cell debris was removed by centrifugation
at 15,000 rpm for 20 min. The proteins were purified through
epitope tag as previously described [16].
For purification of recombinant histone H3 and H3 mutant, we
followed the procedure described by Luger et al. [38]. In short, the
inclusion body containing histone H3 was resuspended in buffers
containing 6M Urea and passed Sephacryl 200 and SP column
sequentially. Histone H3 eluted from SP column was dialyzed
against water and lyophilized for storage.
Co-immunoprecipitation
For co-immunoprecipitation experiment, ,150 nM Flag-
Ash2L/His-RbBP5 complex and ,180 nM His-MLL1
SET were
mixed together with 7.5 mM H3, 10 mM AdoHcy or both. The
purification using M2 agarose beads was carried out in BC150
buffer containing 20 mM Tris-HCl pH 7.9, 150 mM KCl,
0.2 mM EDTA and 20% glycerol at 4uC for 4–6 hours and
proteins were eluted from beads by excess FLAG peptide.
Protein Identification by LC-Tandem MS
Samples were denatured in a buffer containing 20 mM HEPES
buffer, pH 7.5, and 8 M Urea. Upon reduction (10 mM DTT,
37uC, 30 min) and alkylation (50 mM iodoacetamide, 37uC,
30 min) of the cysteines, proteins were digested with 500 ng of
sequencing-grade modified trypsin (Promega) after reducing the
urea concentration to 1.5 M. Resulting peptides were resolved on
a nano-capillary reverse phase column (Picofrit column, New
Objectives) using water: acetonitrile gradient system at 300 nl/min
and directly introduced into an ion-trap mass spectrometer
(LTQ XL, ThermoFisher). Mass spectrometer was operated in a
data-dependent mode to collect MS/MS spectra on the 5 most
intense ions from each full MS scan. Proteins were identified by
searching the data against human IPI database (v 3.41) appended
with decoy (reverse) database using X!Tandem/Trans-Porteomic
Pipeline software suite. All proteins with a Protein Prophet
probability score of .0.9 were considered to be positive
identifications.
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Reactions were carried out at 30uC for 1 hour in the presence of
[
3H]-SAM (S-adenosyl-L- [methyl-
3H] methionine) as previously
described [1]. 60 mM unmodified, mono-, di-, and tri-methylated
H3 K4 peptides (Millipore) or 10 mM recombinant H3 was used as
substrates. Molar concentration of Ash2L, RbBP5/Ash2L and
MLL1
SET proteins for each reaction were indicated in text or
figure legend. At least three independent experiments were carried
out for each figure.
SAM Binding Assay by UV Cross-linking
Binding assay was performed as previously described with small
modifications [34]. Proteins were incubated with 0.5 mCi of
S-adenosyl-L- [methyl-
3H] methionine (82 ci/mmol, Amersham
TRK581) in 20 ml reaction overnight at 4uC and added to 96-well
plate on ice. After 30 mins exposure from a handheld UV lamp
(short wave, 254 nm) at a distance of 10 cm away from samples,
the proteins were separated on SDS-PAGE, stained with
Coomassie, and subjected to fluorography. For most SAM binding
assays, ,3 mM of Ash2L or Ash2L/RbBP5 or MLL1
SET were
used. Duplicate gels were run for straight Coomassie staining as
loading controls. At least three independent experiments were
carried out and representative results were presented. For
competitive binding, 0.35 mM unlabeled SAM or ATP was
incubated with proteins in the presence of [
3H]-SAM.
Thermal Shift assay
The thermal shift assay was carried out using Thermofluor 384
ELS system. The Thermofluor contains a heating/cooling device
for temperature control and a charge-coupled device (CCD)
detector for simultaneous imaging of the fluorescence changes in
the wells of the microplate. Protein unfolding was examined by
monitoring the fluorescence of ANS (1-anilinonaphthalene-8-
sulfonic acid) as a function of temperature with Ex/Em: 475/
525 nm. All samples were prepared in quadruplicates and
contained proteins at 10 mM concentrations in 50 mM Tris,
pH 7.5, 150 mM NaCl buffer and 50 mM ANS. To limit the
evaporation the samples were covered using mineral oil. Thermal
denaturation was monitored by heating the samples from 25 to
65uC. The Tm, which is the midpoint of the protein unfolding
transition, is summarized in Table S1. For proteins that do not
have folded tertiary structure, we observed no thermal transition
and the Tm was not determined.
RNAi Knockdown and Rescue Experiment
HeLa cells [1] were transfected with siRNA duplexes (Dharma-
con) using oligofectamine (Invitrogen) according to the manufac-
turer’s instruction. Transfection of 1 mg Myc-Ash2L plasmid was
performed 24 hour after the second of two rounds of siRNA
treatment. Cells were harvested 24 hour after Ash2L over-
expression. Ash2L small interfering RNAs (siRNAs) targeted 59-
CCGAGTAACTAACTTATTTAA-39 of Ash2L 39UTR [39].
Antibodies
Antibodies for immunoblots were obtained commercially: anti-
Ash2L (Active Motif, 39099); anti-RbBP5 (Bethyl, A300-109A),
anti-FLAG (Sigma, monoclonal M2 antibody, F1804); M2 agarose
(Sigma, A2220), anti-His (Qiagen, Penta his antibody, 34660);
anti-myc (Millipore, 05-724), anti-H3 trimethyl K4 (Abcam,
ab8580), anti-H3 dimethyl K4 (Abcam, ab32356), anti-H3 mono
methyl K4 (Abcam, ab8895), anti-H3 (Upstate, 05928).
Supporting Information
Figure S1 (A) Coomassie gels for purified recombinant proteins
or protein complexes from E. coli: MLL1SET, WDR5, RbBP5,
Ash2L, Ash2L/RbBP5 and Ash2L-C/RbBP5-N complex. (B) The
Coomassie gel for purified recombinant proteins used in Figure 3B:
RbBP5, RbBP5FD/SG, Ash2L, Ash2L R343A and MLL1SET.
(C) The Coomassie gel for purified MLL1SET and MLL1SET
mutant proteins as indicated on top.
Found at: doi:10.1371/journal.pone.0014102.s001 (1.03 MB TIF)
Figure S2 Sequence alignment of SPRY domains of Ash2L
homologues in human, Drosophila, Saccharomyces cerevisiae and
Tetrahymena thermophila. The conserved Argnine residues are
highlighted by square (æ). Several aromatic residues were
highlighted by (*).
Found at: doi:10.1371/journal.pone.0014102.s002 (0.63 MB TIF)
Figure S3 Comparison of SET domain structures for DIM5 and
MLL1SET. Left, DIM5 SET domain is depicted in brown and H3
is in green. SAM is locked in position by residues 281-283 on one
side and W318 on the other side. Right, MLL SET domain is
depicted in pink and H3 is in blue. In this non-canonical SET
domain structure, SAM and H3 are not optimally aligned. Both
structures were adapted from the original structure studies [1,2].
Found at: doi:10.1371/journal.pone.0014102.s003 (1.10 MB TIF)
Table S1 Table for Tm derived from the thermal melting curves
for wild type Ash2L and RbBP5 proteins as well as their mutants
as indicated. RbBP5 330-363 showed no fluorescence transition in
the assay, suggesting the lack of secondary structure for this
peptide.
Found at: doi:10.1371/journal.pone.0014102.s004 (0.12 MB TIF)
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